蛋白磷酸酶6通过mTORC1通路调控代谢功能障碍相关脂肪性肝炎
本研究在小鼠模型中证实丝氨酸/苏氨酸磷酸酶PPP6C是FGF21的直接靶点,肝脏PPP6C缺失加速MASH进展并阻断FGF21疗效;PPP6C与βKlotho相互作用并去磷酸化TSC2,抑制mTORC1;MASH患者肝脏PPP6C表达降低而TSC2磷酸化升高。
要点
- PPP6C是FGF21信号在肝细胞中的下游必需介质。
- 肝脏PPP6C缺失加速小鼠MASH进展并阻断FGF21对MASH的作用。
- MASH患者肝脏PPP6C表达降低而TSC2磷酸化升高。
核心结论
- PPP6C是FGF21信号在肝细胞中必需的下游介质,靶向PPP6C可能为治疗人类MASH提供治疗潜力。
研究设计与样本
- 研究使用肝脏特异性PPP6C和βKlotho敲除小鼠及其野生型同窝对照,分别喂食AMLN饮食16周或CDA-HFD饮食8周,随后每日皮下注射重组FGF21(0.5 mg/kg)或溶媒4周。
- 采用质谱分析鉴定PPP6C为βKlotho结合蛋白,并用体外磷酸酶实验评估FGF21对PPP6C活性的影响。
- 分析MASH患者人体样本中PPP6C的表达。
主要发现
- 鉴定出丝氨酸和苏氨酸磷酸酶PPP6C为FGF21的直接靶点。
- 在喂食AMLN饮食或CDA-HFD的小鼠中,肝脏PPP6C缺失加速MASH进展,并阻断FGF21对MASH的作用。
- 机制上,PPP6C在FGF21处理时与核心受体βKlotho相互作用,并直接去磷酸化结节性硬化复合物2(TSC2)的Ser939和Thr1462位点,从而抑制mTORC1并促进TFE3和Lipin1入核。
- 在MASH患者肝脏中,PPP6C表达水平降低而TSC2磷酸化升高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Metabolic dysfunction-associated steatohepatitis (MASH) is a serious chronic liver disease for which therapeutic options are limited. Although fibroblast growth factor 21 (FGF21) analogs have shown therapeutic promise for MASH in multiple preclinical and clinical studies, their underlying mechanisms of action remain elusive. METHODS: Liver-specific PPP6C and βKlotho knockout mice and their wild-type littermates were fed an AMLN (Amylin liver NASH) diet for 16 weeks or a CDA-HFD (choline-deficient, L-amino acid-defined, high-fat diet) for 8 weeks, followed by daily subcutaneous injection of recombinant FGF21 (0.5 mg/kg) or vehicle for 4 weeks. A mass spectrometry assay identified PPP6C as a βKlotho-binding protein. An in vitro phosphatase assay was used to evaluate the effects of FGF21 on PPP6C activity. PPP6C expression was also analyzed in human samples from patients with MASH. RESULTS: We identified serine and threonine phosphatase PPP6C as a direct target of FGF21. Hepatic PPP6C deficiency accelerates MASH progression in mice fed an AMLN diet or CDA-HFD, which blocks the effect of FGF21 on MASH. Mechanistically, PPP6C is sufficient to interact with the coreceptor βKlotho upon FGF21 treatment and directly dephosphorylates tuberous sclerosis complex 2 (TSC2) at Ser939 and Thr1462, thereby inhibiting mTORC1 and promoting nuclear entry of TFE3 and Lipin1. In the livers of patients with MASH, expression levels of PPP6C are decreased whereas TSC2 phosphorylation is elevated. CONCLUSIONS: PPP6C acts as a fundamental downstream mediator essential for FGF21 signaling in hepatocytes and targeting PPP6C by FGF21 may offer therapeutic potential for treating MASH in humans. IMPACT AND IMPLICATIONS: Metabolic dysfunction-associated steatohepatitis (MASH) is a severe chronic liver disease that increases susceptibility to more severe cirrhosis and hepatocellular carcinoma. Effective therapeutic strategies for MASH remain an unmet need. Herein, we have identified serine and threonine protein phosphatase PPP6C as a negative regulator of MASH progression in mice and humans. PPP6C activity is increased by FGF21 via an autocrine effect mediated by FGFRs/βKlotho in hepatocytes. Pharmacological administration of FGF21 protects against MASH pathology at least in large through the interaction between βKlotho and PPP6C and PPP6C-mediated dephosphorylation of TSC2 in hepatocytes. This study implies that pharmacological approaches targeting PPP6C activity may offer attractive prospects for treating liver fibrosis and MASH.
引用
- Liu Z, Wei S, Jiang Y, et al. Protein phosphatase 6 regulates metabolic dysfunction-associated steatohepatitis via the mTORC1 pathway. J Hepatol. 2025. PMID: 39947331. doi:10.1016/j.jhep.2025.02.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。